The firm posted 2 percent overall revenue growth as strength in Europe and the Americas was offset by softness in China and the rest of Asia.

Diagnostics' products, including its in-development point-of-care molecular diagnostics system, in Saudi Arabia and 18 other MENA countries.

The firm posted 2 percent overall revenue growth as strength in Europe and the Americas was offset by softness in China and the rest of Asia.

Last week, readers were most interested in a story about Hologic's plans to go private via an acquisition by two private equity firms.

The firm posted 2 percent overall revenue growth as strength in Europe and the Americas was offset by softness in China and the rest of Asia.

NEW YORK – Having recently closed a pre-seed funding round, cancer diagnostics firm Procyon is targeting early 2026 for the UK launch of its urine-based test for early detection of pancreatic cancer.

Analysts and industry watchers forecast a short-term focus on the Breast Health business and increased flexibility for long-term investments.

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.